Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CEBP Focus: Update on Lymphoma

Exposure to Solvents and Risk of Non-Hodgkin Lymphoma: Clues on Putative Mechanisms

Paolo Vineis, Lucia Miligi and Adele Seniori Costantini
Paolo Vineis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Miligi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adele Seniori Costantini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-07-0124 Published March 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Malignant lymphomas are a group of diseases of uncertain etiology. Both environmental factors and genetic susceptibility have been reported as risk factors. We have conducted a population-based case-control study in Italy: all newly diagnosed cases of malignant lymphoma, in males and females ages 20 to 74 years in the 1991 to 1993 period, were identified; the control group was comprised of a random sample of the general population resident in each of the areas under study, stratified by sex and 5-year age groups. Overall, 1,428 non–Hodgkin lymphoma (NHL) cases and 1,530 controls were interviewed. Experts from each geographic area examined questionnaire data and assigned a level of probability and intensity of exposure to a range of chemical groups and individual chemicals. For those in the medium/high level of exposure, there was an increased risk of NHL for exposure to benzene, xylene, and toluene. We have examined the hypothesis that the effect of solvents is related to their immunotoxicity by analyzing the interaction with a previous history of autoimmune disease. We have found an apparent, though not statistically significant, increased risk of NHL in those with both exposure to benzene and a history of autoimmune disease (odds ratio, 16.3; 95% confidence interval, 0.8-321). In addition, an odds ratio of 29.8 (95% confidence interval, 1.4-650.2, based on nine exposed cases) was associated with high-level exposure to benzene in those with a positive family history of malignant hematologic neoplasms. Both hypotheses (i.e., the interaction with autoimmune diseases and with familial predisposition) indirectly suggest that an immunologic mechanism could be involved in lymphomagenesis from solvents. (Cancer Epidemiol Biomarkers Prev 2007;16(3):381–4)

Introduction

Malignant lymphomas are a group of diseases of uncertain etiology. They are malignancies of the cells of the immune system; thus, it seems suggestive that immunologic conditions may be related to the occurrence of this group of cancers. A more than 100-fold increased risk of non–Hodgkin lymphoma (NHL) has been described among renal and cardiac transplant recipients receiving immunosuppressive therapy even after only 1 year of latency (1). An increased NHL incidence is also found among subjects with primary immunodeficiency (e.g., ataxia telangiectasia), acquired immunodeficiency (HIV), and autoimmune diseases (e.g., lupus erythematosus, coeliac disease, and Sjögren syndrome; refs. 2, 3). Other autoimmune diseases (such as, e.g., diabetes type 1, multiple sclerosis, or rheumatoid arthritis) have been associated with the risk of NHL in some studies but not in others (2, 3). In relation to environmental exposures, recent studies have suggested an association between NHL and exposure to organic solvents (4-7). Organic solvents represent a class of chemicals that have been used in many industrial sectors, and exposure is also widespread among the general population. We have published in detail, elsewhere, the association between organic solvents and NHL, based on a large population-based multicenter case-control study in Italy (8). Solvents are suspected of exerting an immunotoxic effect (9).

Familial/genetic susceptibility has also been suggested. In one recent study, the risk of NHL was elevated in relatives of NHL cases [hazard ratio, 2.9; 95% confidence interval (95% CI), 0.95-8.53]; the aggregation seemed to be stronger for siblings (hazard ratio, 7.6; 95% CI, 0.98-58.8) and for male relatives (hazard ratio, 6.2; 95% CI, 0.77-50.0; ref. 10). These results are consistent with previous findings of familial aggregation of NHL. Evidence on genetic susceptibility for NHL is still scanty, except for some specific genetic syndromes. These fall into five main categories: DNA repair defects (e.g., Bloom, Fanconi, and Ataxia teleangectasia), defects leading to secondary mutations, tumor suppressor defects (e.g., Down syndrome and Li-Fraumeni), immunodeficiency (e.g., X-linked lymphoproliferative disorder), and defects in apoptosis (11). Both familial aggregation and the mechanisms involved in familial syndromes shed light on potential pathways involved in lymphomagenesis and can contribute to the identification of candidate genes. Currently, the search for candidate genes points mainly to factors regulating immune function. Several genes have been proposed, most coding for inflammatory and regulatory cytokines (TNF, IL-α1, IL-1β, IL-1RN, IL-6, and LTA), Th1/Th2 cytokines (IL-10, IL-4, and IL-4RA), or chemokines (IL-8, CCR2, CCR5, and SDF-1) and others involved in innate immunity (myeloperoxidase, MPO).

The present study examines hypotheses regarding the putative mechanisms of action of solvents in lymphomagenesis, based on a large multicenter case-control study conducted in Italy. Because the main hypothesis concerning the mechanism of action of solvents in lymphomagenesis has been immunotoxicity, we focused on the interaction between autoimmune disease and solvents. We also examined effect modification by family history of hematolymphopoietic malignancy.

Materials and Methods

We have conducted a population-based case-control study in 11 areas in Italy. We included all newly diagnosed cases of NHL that occurred during the period 1991 to 1993 among residents aged 20 to 74 years. Eight of the 11 areas were chosen because of the presence of manufacturing industries where solvents have been largely used. In each center, NHL cases were identified through periodic surveys of the hospital and pathology departments where such cases are diagnosed and treated and in some hematologic centers in Milan, Pavia, Bologna, and Rome, outside the areas under study. In Varese, all cases were identified through the Varese Cancer Registry. As a result of this systematic case ascertainment, it is unlikely that many cases were lost. NHL cases were classified following the Working Formulation.4 If the original diagnosis was outside the Working Formulation definitions, the cases was reclassified within the Working Formulation by a pathologist experienced in the field. Following the Working Formulation, chronic lymphocytic leukemia cases were grouped in the “small lymphocytic consistent with chronic lymphocytic leukemia” category. All doubtful NHL diagnoses (i.e., diagnoses for which the local pathologist had expressed uncertainties about the allocation to a specific NHL category) and, additionally at random, one case of five were submitted to a panel of three pathologists to validate diagnoses. In total, 334 cases were reviewed, and the NHL diagnosis was confirmed for all cases.

The control group was comprised of a random sample of the general population, resident in each of the areas under study, stratified by sex and 5-year age groups. The size of the control group was somewhat greater than the largest diagnostic group (NHL and chronic lymphocytic leukemia cases combined). Details on case ascertainment and recruitment and control sampling procedures have been described previously (8).

We conducted in-person interviews primarily at the interviewee's home to obtain information on education; relevant lifestyle factors, such as tobacco smoking and beverage consumption; a detailed occupational history (including detailed data on specific jobs through the use of a job-specific questionnaire); extra-occupational exposure to solvents and pesticides; hair-dye use; lifelong residential history; previous diseases; use of diagnostic or therapeutic X-rays; specific medications; family medical history; and reproductive history. The medical history contained detailed questions on several autoimmune diseases, including date of diagnosis. We focus here on a history of lupus, rheumatoid arthritis, and sclerodermia.

The approach used in this study to assess exposure used job- or industry-specific questionnaires with subsequent expert ratings to assign exposure to a defined list of agents. Industrial hygiene experts from each geographic area examined questionnaire data and assessed the level of probability, and intensity, of exposure to groups or classes of solvents as well as certain individual substances. The assessors were blind to case-control status. The experts made exposure judgments for the following categories: a general category “solvents” covering all substances used as solvents and specific chemical classes (aromatic hydrocarbons, chlorinated hydrocarbons, aliphatic hydrocarbons, and oxygenated derivative hydrocarbons). Furthermore, when the information was sufficient to assess individual chemicals, they made exposure judgments for aromatic hydrocarbons (benzene, styrene, xylene, and toluene), among chlorinated hydrocarbons (dichloromethane, tetrachloroethylene, trichloroethylene, 1,1,1-trichloroethane, and chloroform), and among oxygenated derivative hydrocarbons (1,4-dioxane).

Exposures were rated on two scales: “probability” represented the certainty/uncertainty of exposure based on knowledge of the materials used and technologies applied in the particular activity/production process reported in a given calendar period. It was classified into three levels: low, medium, and high. The second scale was “intensity,” which represented the estimated concentration of the agent in the work environment and was measured on a four-point scale: very low, low, medium, and high. The first class of intensity (“very low”) was used for subjects judged to have occupational exposure intensities comparable to the upper end of the reference range of exposures for the general population. “Low level” intensity was assigned when workplace exposure was judged to be low because of control measures but nevertheless higher than in the general population. Medium exposure was assigned to subjects who worked where only moderate or poor control measures were judged to exist. The highest category was used for subjects who worked in workplaces with no control measures. To ensure a standardized approach, the assessors were centrally trained prior and periodically during their independent evaluations of questionnaires. Furthermore, to reduce the exposure assessment variability of the different experts, a job-exposure matrix was developed, collecting the minimum overall consensus for the most frequent job titles/sectors in the study areas, and this was used as baseline for the individual exposure assessment. Participants were asked to provide a family history of illness (including cancer) among first-degree relatives. Illness type was reported in an open-ended response. We asked also age at diagnosis for each illness and the cause of, and age at, death of respondent's mother and father.

Data Analysis

Data analyses were done with SAS (SAS Institute, Cary, NC). Odds ratios (OR) and the corresponding 95% CI were calculated. All analyses were done using multiple logistic regression models, taking into account relevant potential confounders (sex, age, area, and education level). Subjects who were never exposed to any of the listed chemicals were used as the referent population.

Results

We were able to interview personally 84.6% of NHL cases and 96.5% of controls in the eight areas where exposure assessment for solvents was completed and interviewed the remainder by proxy (for details, see ref. 8). For proxy respondents, we have evaluated the distribution of some confounding factors between direct responders and proxies. We observed that the distribution by sex, smoking, and educational level was very similar in the two groups (8).

Analyses for specific chemical substances revealed elevated NHL risks associated with medium/high exposures to toluene (OR, 1.8; 95% CI, 1.1-2.8), xylene (OR, 1.7; 95% CI, 1.0-2.6), and benzene (OR, 1.6; 95% CI, 1.0-2.4). Table 1 shows the distribution of exposure to selected solvents and a history of previous autoimmune diseases. We excluded one center (Imperia) because the prevalence of rheumatoid arthritis was not credible and was much higher than in population surveys. Table 1 shows an apparent, though not statistically significant, increased risk of NHL in those with both exposure to benzene and a history of autoimmune disease. Table 2 shows the interaction between solvent exposure and a family history for a malignancy of the hematolymphopoietic system. A strong and statistically significant association is shown, in particular with benzene (OR, 29.8; 95% CI, 1.4-650.2), for exposure intensity greater than “low.” Interactive terms between benzene exposure and autoimmune disease or family history were not statistically significant (P > 0.05).

View this table:
  • View inline
  • View popup
Table 1.

Exposure to solvents with probability level and exposure level >1 (see text)

View this table:
  • View inline
  • View popup
Table 2.

Cases and controls exposed to solvents with probability level>1 and exposure level>1, by family history (at least one hematolymphopoietic malignancy in the first-degree relatives)

Mechanistic Hypothesis

In the present study, the data suggest that solvent-related lymphomagenesis can be modulated by a history of autoimmune diseases and by a family history of hematolymphopoietic malignancies, the first observation of such possible modulatory effects.

The IARC has classified benzene as carcinogenic to humans (group 1) based on an increased risk of hematopoietic malignancies, notably acute myeloid leukemia, but not NHL. Among the same group of aromatic hydrocarbons, styrene was classified as possibly carcinogenic to humans (group 2B); xylene and toluene were not classifiable as to their carcinogenicity for humans (group 3). Among chlorinated hydrocarbons, trichloroethylene and tetrachloroethylene were both classified by IARC as probably human carcinogens (group 2A); dichloromethane was recently evaluated as possibly carcinogenic to humans (group 2B); 1,1,1-trichloroethane was considered not classifiable as to its carcinogenicity to humans.5

The main hypothesis concerning the mechanism of action of solvents in lymphomagenesis has been immunotoxicity. Immunotoxicity studies on organic solvents suggested that professional and/or environmental exposure may determine effects on the immune system of humans. Among aromatic solvents, most of the studies referred to benzene. This chemical may affect both humoral and cellular acquired immunity in animals. The Agency for Toxic Substances and Disease Registry reported in a review on benzene (9) that an association between benzene exposure and adverse effects on functional immunity is supported by the literature; in particular, benzene determines an immunosuppressive response. Benzene has a greater depressive effect on T lymphocytes than B cells (12). Biro et al. found that solvents, such as benzene and styrene, activate peripheral lymphocytes and cause changes in the prevalence of CD25+/CD4+ T lymphocytes (13). In a study among workers exposed to benzene concentrations lower than 15 ppm, depression of the circulating B-lymphocyte level was induced (14). Other disparate and immunologic effects in workers exposed to solvents have been described (15-18). In a study in mice, immunotoxicity induced by benzene treatment alone was characterized by involution of thymic mass and suppression of both B- and T-cell mitogenesis (19). This study also suggested that toluene, in sufficient amounts, may have an antagonistic effect on benzene immunotoxicity in mice (19).

We have tested in our data set a new hypothesis (i.e., an interaction between a history of autoimmune disease and solvent exposure). We found a possible interaction between a history of autoimmune diseases and solvent exposure, which suggests that already existing immunologic impairment can increase the risk of NHL in subjects exposed to solvents and, in particular, to benzene. However, the association needs to be confirmed; biological plausibility is also currently lacking, as the immunosuppressive effect of solvents would be expected to attenuate the manifestations of autoimmune disease. We found also a stronger association between exposure to benzene and NHL in the presence of a family history of hematolymphopoietic malignancies. Most hypotheses concerning genetic predisposition to NHL, in fact, refer to genes involved in immune function. Thus, genetic predisposition to benzene-related lymphomagenesis deserves further investigation.

Appendix A

The following are the members of the Working Group: Alessandra Benvenuti, David Kriebel, Vanessa Bolejack, Rosario Tumino, Valerio Ramazzotti, Stefania Rodella, Emanuele Stagnaro, Paolo Crosignani, Dino Amadori, Dario Mirabelli, Letizia Sommani, Isabella Belletti, Loredana Troschel, Luciano Romeo, Giuseppe Miceli, Giulio Andrea Tozzi, and Igino Mendico.

Acknowledgments

We thank S. Alberghini Maltoni, S. Barcellini, G. Barni, L. Bellesini, V. Cacciarini, R. Carlini, M. Casale, G. Castellino, G. Cremaschi, L. Davico, A. Fiorio, R. Gibilisco, L. Guzzo, R. Hirvas, S. Legrotti, L. Migliaretti, R. Monteleone, G. Osella, T. Palma, G. Panizza, C. Picoco, G. Piergiovanni, G. Righetti, R. Sguanci, M. Tedeschi, D. Tiberti, G. Tonini, P. Trada, T. Vescio, and M. Zanetta for their cooperation; Giuseppe Gorini and Angela Veraldi for their contribution and suggestions; and the members of the panel of pathologists (S. di Lollo, L. Fiore Donati, U. Magrini, F. Menestrina, D. Novero, G. Palestro, A. Paolucci and M. Paulli) and the clinical department staffs for their involvement in patient recruitment.

Footnotes

  • ↵4 For details, see http://training.seer.cancer.gov/ss_module08_lymph_leuk/lymph.

  • ↵5 http://www-cie.iarc.fr/

  • Grant support: National Cancer Institute grant CA51086, European Community (Europe against Cancer Programme), and Italian Alliance against Cancer (Lega Italiana per la Lotta contro i Tumori).

    • Accepted December 21, 2006.
    • Received December 19, 2006.

References

  1. ↵
    Scherr PA, Mueller NE. Non Hodgkin's lymphomas. In: Schottenfeld D, Fraumeni JJ, editors. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press; 1996. p. 920–45.
  2. ↵
    Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524–34.
    OpenUrlCrossRefPubMed
  3. ↵
    Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1–12.
    OpenUrlPubMed
  4. ↵
    Travier N, Gridley G, De Roos, et al. Cancer incidence of dry cleaning, laundry and ironing workers in Sweden. Scand J Work Environ Health 2002;28:341–8.
    OpenUrlPubMed
  5. Rego MA, Sousa CS, Kato M, et al. Non-Hodgkin's lymphomas and organic solvents. JOEM 2002;44:874–81.
  6. Mao Y, Hu J, Ugnat AM, White K. Non-Hodgkin's lymphoma and occupational exposure to chemicals in Canada. Canadian cancer registries epidemiology research group. Ann Oncol 2000;11 Suppl 1:69–73.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Blair A, Petralia SA, Stewart PA. Extended mortality follow-up of a cohort of dry cleaners. Ann Epidemiol 2003;13:50–6.
    OpenUrlCrossRefPubMed
  8. ↵
    Miligi L, Seniori Costantini A, Benvenuti A, et al. Occupational exposure to solvents and the risk of lymphomas. Epidemiology 2006;17:552–61.
    OpenUrlCrossRefPubMed
  9. ↵
    Agency for Toxic Substances and Disease Registry (ATSDR) U.S. Department of Health and Human Services, Public Health Services. Toxicological profile for benzene (Draft for Public Comment), September 2005: http://www.atsdr.cdc.gov/toxprofiles/tp3.html.
  10. ↵
    Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 2004;13:1415–21.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Segel GB, Lichtman MA. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis 2004;32:246–61.
    OpenUrlCrossRefPubMed
  12. ↵
    Gist GL, Burg JR. Benzene: a review of the literature from a Health Effects Perspective Exposure and Disease Registry Branch, Division of Health Studies, Agency for Toxic Substances and Disease Registry (ATSDR), U.S. Department of Health and Human Services, Public Health.
  13. ↵
    Biro A, Pallinger E, Major J, et al. Lymphocyte phenotype analysis and chromosome aberration frequency of workers occupationally exposed to styrene, benzene, polycyclic aromatic hydrocarbons or mixed solvents. Immunol Lett 2002;81:133–40.
    OpenUrlCrossRefPubMed
  14. ↵
    Bogadi-Sare A, Zavalic M, Trosic I, Turk R, Kontosic I, Jelcic I. Study of some immunological parameters in workers occupationally exposed to benzene. Int Arch Occup Environ Health 2000;73:397–400.
    OpenUrlCrossRefPubMed
  15. ↵
    Zeman K, Tchorzewski H, Baj Z, et al. The effects of occupational exposure to hydrocarbons on some immune parameters of workers of the phenol division of a petrochemical plant. Int J Occup Med Environ Health 1990;3:399–407.
  16. Lange A, Smolik R, Zatonski W, Szymanska J. Serum immunoglobulin levels in workers exposed to benzene, toluene and xylene. Int Arch Arbeitsmed 1973;31:37–44.
    OpenUrlCrossRefPubMed
  17. Smolik R, Grzybek-Hryncewicz K, Lange A, Zatonski W. Serum complement level in workers exposed to benzene, toluene and xylene. Int Arch Arbeitsmed 1973;31:243–7.
    OpenUrlCrossRefPubMed
  18. ↵
    Lange A, Smolik R, Zatonski W, Glazman H. Leukocyte agglutinins in workers exposed to benzene, toluene and xylene. Int Arch Arbeitsmed 1973;31:45–50.
    OpenUrlCrossRefPubMed
  19. ↵
    Hsieh GC, Parker RD, Sharma RP, Hughes BJ. Subclinical effects of groundwater contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. Arch Toxicol 1990;64:320–8.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 16 (3)
March 2007
Volume 16, Issue 3
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Exposure to Solvents and Risk of Non-Hodgkin Lymphoma: Clues on Putative Mechanisms
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Exposure to Solvents and Risk of Non-Hodgkin Lymphoma: Clues on Putative Mechanisms
Paolo Vineis, Lucia Miligi and Adele Seniori Costantini
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 381-384; DOI: 10.1158/1055-9965.EPI-07-0124

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Exposure to Solvents and Risk of Non-Hodgkin Lymphoma: Clues on Putative Mechanisms
Paolo Vineis, Lucia Miligi and Adele Seniori Costantini
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 381-384; DOI: 10.1158/1055-9965.EPI-07-0124
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Appendix A
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Environmental and Behavioral Factors and the Risk of Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma Secondary to Cancer Chemotherapy
Show more CEBP Focus: Update on Lymphoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement